Meidan Ying

7.0k total citations
95 papers, 3.3k citations indexed

About

Meidan Ying is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Meidan Ying has authored 95 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Molecular Biology, 21 papers in Cancer Research and 16 papers in Oncology. Recurrent topics in Meidan Ying's work include Ubiquitin and proteasome pathways (24 papers), Retinoids in leukemia and cellular processes (17 papers) and Acute Myeloid Leukemia Research (12 papers). Meidan Ying is often cited by papers focused on Ubiquitin and proteasome pathways (24 papers), Retinoids in leukemia and cellular processes (17 papers) and Acute Myeloid Leukemia Research (12 papers). Meidan Ying collaborates with scholars based in China, United States and Macao. Meidan Ying's co-authors include Qiaojun He, Bo Yang, Ji Cao, Hong Zhu, Xuejing Shao, Yuan Meng, Rong Dong, Fangjie Yan, Jiang Li and Tao Yuan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Meidan Ying

91 papers receiving 3.3k citations

Peers

Meidan Ying

ONCOL

PRM

IMMUN

Benjamin D. Hopkins United States

Zhengzhi Zou China

Qiong Shi China

Zachary T. Schafer United States

Sang‐Gu Hwang South Korea

Zhongmei Zhou China

Tongsen Zheng China

Dong‐Sheng Pei China

Gerta Hoxhaj United States

John Brognard United States

Benjamin D. Hopkins United States

Meidan Ying

3.0k ×1.3

940 ×1.2

979 ×1.4

ONCOL

576 ×1.0

PRM

448 ×0.9

IMMUN

Citations per year, relative to Meidan Ying Meidan Ying (= 1×) peers Benjamin D. Hopkins

Countries citing papers authored by Meidan Ying

Since Specialization

Citations

This map shows the geographic impact of Meidan Ying's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meidan Ying with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meidan Ying more than expected).

Fields of papers citing papers by Meidan Ying

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meidan Ying. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meidan Ying. The network helps show where Meidan Ying may publish in the future.

Co-authorship network of co-authors of Meidan Ying

This figure shows the co-authorship network connecting the top 25 collaborators of Meidan Ying. A scholar is included among the top collaborators of Meidan Ying based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meidan Ying. Meidan Ying is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xiang, Senfeng, Pengfei Chen, Haoyang Cai, et al.. (2025). Disruption of the KLHL37–N-Myc complex restores N-Myc degradation and arrests neuroblastoma growth in mouse models. Journal of Clinical Investigation. 135(14).

He, Min, Yuwei Wang, Jiabin Cai, et al.. (2024). Robot-assisted resection of renal tumor in children and comparison with laparoscopic surgery. BMC Surgery. 24(1). 325–325. 1 indexed citations

Wu, Mingfei, Wei Wang, Tao Liu, et al.. (2024). Discovery of a potent CDKs/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML. European Journal of Medicinal Chemistry. 275. 116539–116539. 5 indexed citations

Chen, Yingqian, et al.. (2023). Driving the degradation of oncofusion proteins for targeted cancer therapy. Drug Discovery Today. 28(6). 103584–103584. 3 indexed citations

He, Min, Jiabin Cai, Can Lai, et al.. (2022). Neoadjuvant transcatheter arterial chemoembolization and systemic chemotherapy for the treatment of undifferentiated embryonal sarcoma of the liver in children. World Journal of Clinical Cases. 10(19). 6437–6445. 4 indexed citations

Chen, Yingqian, Chen Wang, Ning Zhang, et al.. (2021). Advances in targeted therapy for osteosarcoma based on molecular classification. Pharmacological Research. 169. 105684–105684. 58 indexed citations

Xiang, Senfeng, Pengfei Chen, Ji Cao, et al.. (2021). Targeting Cul3-scaffold E3 ligase complex via KLHL substrate adaptors for cancer therapy. Pharmacological Research. 169. 105616–105616. 10 indexed citations

Zhu, Hong, Fangjie Yan, Tao Yuan, et al.. (2020). USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ. Cancer Research. 80(11). 2204–2216. 133 indexed citations

Zhu, Hong, Yan Hu, Chenming Zeng, et al.. (2020). The SIRT2-mediated deacetylation of AKR1C1 is required for suppressing its pro-metastasis function in Non-Small Cell Lung Cancer. Theranostics. 10(5). 2188–2200. 16 indexed citations

10.

Sun, Yanan, Xianrong Lai, Yu Yan, et al.. (2019). Inhibitor of DNA binding 1 (Id1) mediates stemness of colorectal cancer cells through the Id1-c-Myc-PLAC8 axis via the Wnt/β-catenin and Shh signaling pathways. SHILAP Revista de lepidopterología. 2 indexed citations

11.

Cao, Ji, Rong Dong, Jiang Li, et al.. (2018). LncRNA-MM2P Identified as a Modulator of Macrophage M2 Polarization. Cancer Immunology Research. 7(2). 292–305. 132 indexed citations

12.

Zhu, Hong, Dandan Wang, Tao Yuan, et al.. (2018). Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis. Cancer Research. 78(14). 3995–4006. 34 indexed citations

13.

Zhou, Qian, Miao Xian, Senfeng Xiang, et al.. (2017). All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated Macrophages. Cancer Immunology Research. 5(7). 547–559. 121 indexed citations

14.

Li, Yangling, Miao Xian, Bo Yang, Meidan Ying, & Qiaojun He. (2017). Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells. Stem Cell Reports. 8(6). 1617–1629. 47 indexed citations

15.

Wang, Dandan, Ying Chen, Zibo Chen, et al.. (2016). CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation. Molecular Cancer Therapeutics. 15(12). 2916–2925. 38 indexed citations

16.

Cao, Ji, Yijie Wang, Rong Dong, et al.. (2015). Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells. Cancer Research. 75(22). 4839–4851. 57 indexed citations

17.

Ying, Meidan, Xinglu Zhou, Like Zhong, et al.. (2012). Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All- Trans -Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis. Molecular Cancer Therapeutics. 12(2). 195–206. 36 indexed citations

18.

Lou, Siyue, Like Zhong, Xiaochun Yang, et al.. (2012). Efficacy of all-trans retinoid acid in preventing nickel induced cardiotoxicity in myocardial cells of rats. Food and Chemical Toxicology. 51. 251–258. 13 indexed citations

19.

Fang, Yanfen, Xinglu Zhou, Meihua Lin, et al.. (2010). Inhibition of all‐Trans‐retinoic acid‐induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells. Molecular Carcinogenesis. 50(1). 24–35. 20 indexed citations

20.

Luo, Peihua, Xiaochun Yang, Meidan Ying, et al.. (2010). Retinoid-suppressed phosphorylation of RARα mediates the differentiation pathway of osteosarcoma cells. Oncogene. 29(19). 2772–2783. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact